FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast can

[News]

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

More... (http://www.news-medical.net/news/20130912/FDA-grants-Breakthrough-Therapy-designation-to-Syndaxs-entinostat-for-ER2b-breast-cancer.aspx)